Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Muscle Mass, Muscle Strength, and Health-Related Quality of Life in Kidney Transplant Recipients: Results of the TransplantLines Biobank and Cohort Study
Published in: Kidney International Reports
Access to document 10.1016/j.ekir.2024.10.002 document
Introduction: Muscles are crucial for daily activities, and kidney transplant recipients (KTRs) often have reduced muscle mass and strength. We aimed to investigate the potential relationship of muscle mass and strength with physical health-related quality of life (HRQoL) in KTRs. Methods: Data from the TransplantLines Biobank and Cohort Studies were used. Muscle mass was assessed using appendicular skeletal muscle mass index (ASMI) and 24-hour urinary creatinine excretion rate index (CERI). Muscle strength was assessed by handgrip strength index (HGSI). HRQoL was measured using Short Form 36 physical component...
TransplantLines Investigators, Tim J. Knobbe, Gijs M.M. Lenis, Dirk A.J. van der Vossen, Jory Wentink, Daan Kremer, Evelien E. Quint, Antonio W. Gomes-Neto, Robin P.F. Dullaart, Robert A. Pol, Stefan P. Berger, Casper F.M. Franssen, Stephan J.L. Bakker, Adrian Post
Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen
Published in: Haematologica
Access to document 10.3324/haematol.2023.284672 document
Chromosomal translocations in non-Hodgkin lymphoma (NHL) result in activation of oncogenes by placing them under the regulation of immunoglobulin heavy chain (IGH) super-enhancers. Aberrant expression of translocated oncogenes induced by enhancer activity can contribute to lymphomagenesis. The role of the IGH enhancers in normal B-cell development is well established, but knowledge regarding the precise mechanisms of their involvement in control of the translocated oncogenes is limited. The goal of this project was to define the critical regions in the IGH regulatory elements and identify enhancer RNAs (eRNA). We...
Marta Elżbieta Kasprzyk, Weronika Sura, Marta Podralska, Marta Kazimierska, Annika Seitz, Wojciech Łosiewski, Tomasz Woźniak, Jeroen E J Guikema, Arjan Diepstra, Joost Kluiver, Anke Van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
Published in: European Journal of Cancer
Access to document 10.1016/j.ejca.2024.115068 document
Given the rarity of primary central nervous system lymphoma (PCNSL), evaluations of different high-dose methotrexate-(HD-MTX)-based treatment regimens is sparse. This retrospective, multicenter study evaluates clinical characteristics and outcomes (progression-free, overall and disease-specific survival) after five HD-MTX-based polychemotherapeutic regimens and two consolidation therapies. 346 patients with histologically confirmed PCNSL, treated with ≥ 1 cycle HD-MTX-based strategies (≥3g/m2/cycle) were included. The regimens included MATRIX (HD-MTX, HD-AraC, thiotepa, and rituximab), (R)MBVP±HD-AraC (HD-MTX, teniposide/etoposide, carmustine, prednisolone, ± HD-AraC, ± rituximab), (R)MP (HD-MTX, procarbazine, ± rituximab), and a combination of HD-MTX and HD-AraC....
Fleur A. de Groot, Tim J.A. Dekker, Jeanette K. Doorduijn, Stefan Böhringer, Mirian Brink, Ruben A.L. de Groen, Lorraine M. de Haan, F. J.Sherida H. Woei-A-Jin, Troy Noordenbos, Aniko Sijs-Szabo, Mirjam A. Oudshoorn, King H. Lam, Arjan Diepstra, Liane C.J. te Boome, Valeska Terpstra, Lara H. Bohmer, Alina Nicolae, Eduardus F.M. Posthuma, Lianne Koens, Marc F. DurianJeroen Stavast, Marjolein W.M. van der Poel, Myrurgia Abdul Hamid, Wendy B.C. Stevens, Sjo L.M. van Rooij, Rimke S. Oostvogels, Angelika Mühlebner, Karen J. Neelis, Michiel van den Brand, Thomas Tousseyn, Daan Dierickx, Okke de Weerdt, Aart Beeker, Patty M. Jansen, Marie José Kersten, Josée M. Zijlstra, Martine E.D. Chamuleau, Hendrik Veelken, Jacoline C.E. Bromberg, Marcel Nijland, Joost S.P. Vermaat
Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology
Published in: Virchows Archiv
Access to document 10.1007/s00428-024-03933-2
Despite advancements in precision medicine, many cancer patients globally, particularly those in resource-constrained environments, face significant challenges in accessing high-quality molecular testing and targeted therapies. The considerable heterogeneity in molecular testing highlights the urgent need to harmonize practices across Europe and beyond, establishing a more standardized and consistent approach in MP laboratories. Professionals, especially molecular pathologists, must move beyond traditional education to cope with this heterogeneity. This perspective addresses critical issues in molecular pathology (MP), such as limited access to high-quality molecular testing, leading to disparities in cancer...
Marius Ilié, Vivien Lake, Enrique de Alava, Serena Bonin, Sandra Chlebowski, Aurélie Delort, Elisabeth Dequeker, Raed Al-Dieri, Arjan Diepstra, Olli Carpén, Catarina Eloy, Ambrogio Fassina, Falko Fend, Pedro L Fernandez, Gregor Gorkiewicz, Simon Heeke, Rui Henrique, Gerald Hoefler, Pablo Huertas, Michael HummelKarl Kashofer, Jeroen van der Laak, Rocio Martinez de Pablos, Fernando Schmitt, Ed Schuuring, Giorgio Stanta, Wim Timens, Benedikt Westphalen, Paul Hofman
The immune pathology of bursitis in rheumatic inflammatory diseases, degenerative conditions and mechanical stress: A systematic review
Published in: SEMINARS IN ARTHRITIS AND RHEUMATISM
Access to document 10.1016/j.semarthrit.2024.152527 document
OBJECTIVE: To summarize current insights on the immune pathology of bursitis caused by rheumatic inflammatory diseases, degenerative conditions, or mechanical stress and identify knowledge gaps in this field. Data on tenosynovitis pathology was included for comparison. METHODS: We performed a systematic review encompassing an electronic database search of all published literatures in PubMed/MEDLINE from inception to February 13, 2023, investigating the immunological changes occurring in the bursa of patients with inflammatory rheumatic diseases, degenerative conditions or mechanical stress (e.g., impingement syndrome). RESULTS: Thirty-two articles provided data on the...
Anqi Zhang, Elisabeth Brouwer, Maria Sandovici, Arjan Diepstra, William F Jiemy, Kornelis S M van der Geest